CONGESTIVE HEART FAILLURE Elfects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure

To examine the effect of milrinone on myocardial energetics in patients with congestive heart failure, we measured systemic, pulmonary, and coronary hemodynamics in 18 patients before and after intravenous administration of milrinone (125 36 Mg/kg). There was a 45% increase in cardiac index (2.1 ± 0.5 to 3.0 0.6 liters/min/m2; p = .0001), a 39% fall in the pulmonary capillary wedge pressure (28 + 8 to 17 + 8 mm Hg; p = .0001), and a 42% increase in left ventricular external work (3758 ± 1419 to 5340 1598 g-m/min; p = .0001). Both the heart rate-blood pressure product (9624 + 2272 to 9380 2428 mm Hg-beats/min; p = NS) and regional left ventricular myocardial oxygen consumption (7.6 ± 2.9 to 8.1 ± 3.1 ml 02/min; p = NS) were unchanged after milrinone, resulting in a 45% increase in calculated left ventricular external efficiency (p = .004). Although myocardial oxygen consumption did not change, regional great cardiac venous blood flow increased significantly (73 ± 32 to 85 34 ml/min; p .02) as a result of a 30% reduction in regional coronary vascular resistance (1.32 0.99 to 0.93 0.54 mm Hg-min/ml; p = .004), a decrease comparable to the concurrent 37% and 38% falls seen in systemic and pulmonary vascular resistances, respectively. These changes were associated with an 1 1 % fall in the transcoronary arterial-venous oxygen difference (111 + 24 to 99 + 21 ml/02/liter; p = .0001), which is consistent with a primary coronary vasodilator effect of milrinone. Thus, milrinone enhances cardiac performance without a systematic increase in myocardial oxygen consumption, i.e., it increases left ventricular external efficiency. Furthermore, milrinone may improve coronary flow reserve by direct coronary vasodilation and/or reduction in left ventricular diastolic pressure. MILRINONE, a bipyridine compound, causes major hemodynamic improvement in patients with advanced congestive heart failure" 2by a combination of positive inotropic" 3-S and systemic arteriolar vasodilatorl 6 effects. Although a reduction of left ventricular systolic and diastolic pressures might be expected to improve myocardial oxygen balance through reduced myocar-dial work7-9 and improved subendocardial blood flow,'102 respectively, these potential benefits may be From the Charles A. offset by a concurrent increase in oxygen demand resulting from increases in heart rate and contractility.'3 Any net increase in myocardial oxygen demand could be deleterious in patients with limited coronary vasodi-lator reserve due to coronary artery disease or myocar-dial hypertrophy, and might constitute a major limitation to …

[1]  D. Baim,et al.  Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. , 1984, Circulation.

[2]  R. Mates,et al.  Preload-induced alterations in capacitance-free diastolic pressure-flow relationship. , 1984, The American journal of physiology.

[3]  H. Loeb,et al.  Effects of low-dose dobutamine on coronary hemodynamics, myocardial metabolism, and anginal threshold in patients with coronary artery disease. , 1983, Circulation.

[4]  R. Magorien,et al.  The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy. , 1983, American heart journal.

[5]  J. Rouleau,et al.  Captopril in congestive heart failure: improved left ventricular function with decreased metabolic cost. , 1982, American heart journal.

[6]  J. Rouleau,et al.  Alterations in Left Ventricular Function and Coronary Hemodynamics with Captopril, Hydralazine and Prazosin in Chronic Ischemic Heart Failure: A Comparative Study , 1982, Circulation.

[7]  D. Harrison,et al.  Simultaneous measurement of coronary venous blood flow and oxygen saturation during transient alterations in myocardial oxygen supply and demand. , 1982, The American journal of cardiology.

[8]  B. Brundage,et al.  Dobutamine in chronic ischemic heart failure: alterations in left ventricular function and coronary hemodynamics. , 1981, The American journal of cardiology.

[9]  E. Sonnenblick,et al.  Beneficial effect of amrinone on myocardial oxygen consumption during acute left ventricular failure in dogs. , 1981, The American journal of cardiology.

[10]  B. Massie,et al.  Long‐term Vasodilator Therapy for Heart Failure: Clinical Response and its Relationship to Hemodynamic Measurements , 1981, Circulation.

[11]  D. Harrison,et al.  Improved catheter for regional coronary sinus flow and metabolic studies. , 1980, The American journal of cardiology.

[12]  E. Braunwald,et al.  Effects of amrinone on experimental acute myocardial ischaemic injury. , 1980, Cardiovascular research.

[13]  E. Braunwald,et al.  Effects of Amrinone on Myocardial Energy Metabolism and Hemodynamics in Patients with Severe Congestive Heart Failure Due to Coronary Artery Disease , 1980, Circulation.

[14]  L. E. Ford,et al.  Effect of Afterload Reduction on Myocardial Energetics , 1980, Circulation research.

[15]  F. Klocke,et al.  Effects of Preload on the Transmural Distribution of Perfusion and Pressure‐Flow Relationships in the Canine Coronary Vascular Bed , 1980, Circulation research.

[16]  J. Hoffman,et al.  The Role of Autoregulation and Tissue Diastolic Pressures in the Transmural Distribution of Left Ventricular Blood Flow in Anesthetized Dogs , 1979, Circulation research.

[17]  J. S. Janicki,et al.  The metabolic demand and oxygen supply of the heart: physiologic and clinical considerations. , 1979, The American journal of cardiology.

[18]  W. Neill,et al.  Myocardial oxygen supply in left ventricular hypertrophy and coronary heart disease. , 1979, The American journal of cardiology.

[19]  B. Strauer,et al.  Myocardial oxygen consumption in chronic heart disease: role of wall stress, hypertrophy and coronary reserve. , 1979, The American journal of cardiology.

[20]  E. Sonnenblick,et al.  Mechanisms of beneficial effects of vasodilators and inotropic stimulation in the experimental failing ischemic heart. , 1978, The American journal of medicine.

[21]  E. Feigl,et al.  Competition between Sympathetic Vasoconstriction and Metabolic Vasodilation in the Canine Coronary Circulation , 1978, Circulation research.

[22]  F. Klocke,et al.  Coronary blood flow in man. , 1976, Progress in cardiovascular diseases.

[23]  L. Johnson,et al.  Myocardial Blood Flow in Congestive and Hypertrophic Cardiomyopathy: Relationship to Peak Wall Stress and Mean Velocity of Circumferential Fiber Shortening , 1976, Circulation.

[24]  H. Greenberg,et al.  Effects of nitroglycerin on the major determinants of myocardial oxygen consumption. An angiographic and hemodynamic assessment. , 1975, The American journal of cardiology.

[25]  E. Braunwald,et al.  Modification of myocardial infarction size after coronary occlusion. , 1973, Annals of internal medicine.

[26]  E. Braunwald,et al.  Control of myocardial oxygen consumption: physiologic and clinical considerations. , 1971, The American journal of cardiology.

[27]  L. Becker,et al.  Effect of Ischemia and Antianginal Drugs on the Distribution of Radioactive Microspheres in the Canine Left Ventricle , 1971, Circulation research.

[28]  M. Mcgregor,et al.  Effect of Nitroglycerin and Dipyridamole on Regional Coronary Resistance , 1968, Circulation research.

[29]  J. Ross,et al.  Studies on digitalis. XVI. Effects on myocardial oxygen consumption. , 1966, The Journal of clinical investigation.

[30]  J. Ross,et al.  Velocity of contraction as a determinant of myocardial oxygen consumption. , 1965, The American journal of physiology.

[31]  S. Kety,et al.  The measurement of coronary blood flow, oxygen consumption, and efficiency of the left ventricle in man , 1949 .